RCHY1 and Miyoshi myopathy: The percentage of cells in G1 phase in various groups was as follows: ARP-1-Pirh2 vs. ARP-1-ctl, 51.56% ± 3.91% vs. 40.88% ± 2.09%; ARK-Pirh2 vs. ARK-ctl, 49.10% ± 4.32% vs. 31.90% ± 3.98%; and LP-1-Pirh2 vs. LP-1-ctl, 58.90% ± 4.06% vs. 32.40% ± 2.76% (Fig. 5F, P < 0.05) and Furthermore, Pirh2 overexpression increased bortezomib-induced apoptosis in MM cells.